- Home
- SKYE vs GGR Comparison
SKYE vs GGR Comparison
Compare SKYE & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- GGR
- Stock Information
- Founded
- SKYE 2012
- GGR 2011
- Country
- SKYE United States
- GGR Taiwan
- Employees
- SKYE N/A
- GGR N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- GGR Auto Manufacturing
- Sector
- SKYE Health Care
- GGR Consumer Discretionary
- Exchange
- SKYE Nasdaq
- GGR Nasdaq
- Market Cap
- SKYE 108.5M
- GGR 101.1M
- IPO Year
- SKYE N/A
- GGR N/A
- Fundamental
- Price
- SKYE $4.07
- GGR $0.32
- Analyst Decision
- SKYE Buy
- GGR Hold
- Analyst Count
- SKYE 7
- GGR 2
- Target Price
- SKYE $15.50
- GGR $0.50
- AVG Volume (30 Days)
- SKYE 296.3K
- GGR 216.4K
- Earning Date
- SKYE 11-06-2025
- GGR 11-13-2025
- Dividend Yield
- SKYE N/A
- GGR N/A
- EPS Growth
- SKYE N/A
- GGR N/A
- EPS
- SKYE N/A
- GGR N/A
- Revenue
- SKYE N/A
- GGR $289,420,000.00
- Revenue This Year
- SKYE N/A
- GGR N/A
- Revenue Next Year
- SKYE N/A
- GGR $5.00
- P/E Ratio
- SKYE N/A
- GGR N/A
- Revenue Growth
- SKYE N/A
- GGR N/A
- 52 Week Low
- SKYE $1.14
- GGR $0.19
- 52 Week High
- SKYE $6.13
- GGR $1.03
- Technical
- Relative Strength Index (RSI)
- SKYE 59.48
- GGR 37.65
- Support Level
- SKYE $3.96
- GGR $0.34
- Resistance Level
- SKYE $4.35
- GGR $0.36
- Average True Range (ATR)
- SKYE 0.29
- GGR 0.02
- MACD
- SKYE 0.07
- GGR -0.00
- Stochastic Oscillator
- SKYE 62.20
- GGR 11.17
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.